An Open-Label Study of Safety and Immunogenicity in Subjects Following Injection With Two Doses of HEPLISAV

Trial Profile

An Open-Label Study of Safety and Immunogenicity in Subjects Following Injection With Two Doses of HEPLISAV

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs V 270 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 21 Jun 2010 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top